Trump administration’s measles outbreak messaging strikes some as off-key

Experts fear tepid statements from health secretary RFK Jr. and federal agencies reflect hesitancy to endorse importance of vaccination.

February 27, 2025 Check out STAT+

Sponsored By

Julio Cortez/AP On measles outbreak, the Trump administration's messaging strikes some as off-key Experts fear tepid statements from health secretary RFK Jr. and federal agencies reflect hesitancy to endorse importance of vaccination By Andrew Joseph STAT+ | Federal government officials drop out of HIMSS health information conference Federal health officials due to speak at the HIMSS conference in Las Vegas next week have dropped out of the key health tech industry event. By Brittany Trang Trump administration takes aim at bird flu. For now, the cattle will have to wait New USDA plan tackles disease as an issue of economic concern, leaves questions about how to manage the threat H5N1-infected cows pose to people. By Megan Molteni and Helen Branswell Photo illustration: Christine Kao/STAT; Photos: courtesy KdT Ventures, STAT+ | New kids on the block: A new generation of VCs ventures into biotech STAT Who to Know series looks at up-and-coming venture capital firms including Dimension Capital, KdT Ventures, Atria Ventures, Age1, Yosemite, and more. By Allison DeAngelis STAT+ | Why NIH pays universities far more for indirect costs than private foundations Trump administration wants NIH to pay the same as private foundations for research overhead. Experts say the comparison is not a fair one By Anil Oza STAT+ | FDA cancels vaccine advisory committee meeting The meeting is a critical resource for vaccine makers trying to figure out which flu strains to include in their shots for the next flu season. By Lizzy Lawrence Adobe Opinion: The Trump years will be grim for long Covid sufferers The disbanding of an HHS advisory committee may signal the end of federal involvement in addressing long Covid. By Steven Phillips STAT+ | Opinion: There's a better way to get drugs on the market: progressive approval Unlike the accelerated approval process, a progressive approach would benefit both companies and patients. By Eric D. Perakslis and Michael Stebbins

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser